Identification of amino acid residues in PEPHC1 important for binding to the tumor-specific receptor EGFRvIII

Chemical Biology and Drug Design

Volumn 72, Issue 4, 2008, Pages 273-278

  Hansen, Charlotte Lund ^a   Hansen, Paul Robert ^b   Pedersen, Nina ^a   Poulsen, Hans Skovgaard ^a   Gillings, Nic ^a   Kjær, Andreas ^a,b  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Ala scan; Cancer; EGFRvIII; Solid phase peptide synthesis

Indexed keywords

ALANINE DERIVATIVE; AMINO ACID; EPIDERMAL GROWTH FACTOR RECEPTOR 3; HISTIDYLHISTIDYLPHENYLALANYLISOLEUCYLISOLEUCYLGLYCYLPHENYLALANYLMETHIONYLARGINYL ARGININAMIDE; HISTIDYLHISTIDYLPHENYLALANYLISOLEUCYLISOLEUCYLLEUCINAMIDE; HISTIDYLHISTIDYLPHENYLALANYLISOLEUCYLISOLEUCYLLEUCYLGLYCINAMIDE; HISTIDYLHISTIDYLPHENYLALANYLISOLEUCYLISOLEUCYLLEUCYLGLYCYLPHENYLALANINAMIDE; HISTIDYLHISTIDYLPHENYLALANYLISOLEUCYLISOLEUCYLLEUCYLGLYCYLPHENYLALANYLMETHIONINA MIDE; HISTIDYLHISTIDYLPHENYLALANYLISOLEUCYLISOLEUCYLLEUCYLGLYCYLPHENYLALANYLMETHIONYLA RGININAMIDE; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CIRCULAR DICHROISM; CONTROLLED STUDY; HYDROPHOBICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SECONDARY STRUCTURE; PROTEIN TARGETING; RECEPTOR BINDING; SOLID PHASE SYNTHESIS;

AMINO ACID SEQUENCE; AMINO ACIDS; ANIMALS; CELL LINE; CIRCULAR DICHROISM; HUMANS; HYDROPHOBICITY; MICE; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDES; PROTEIN BINDING; RECEPTOR, EPIDERMAL GROWTH FACTOR; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 52649088337     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2008.00706.x     Document Type: Article

References (30)

1. Alper O., Bergmann-Leitner E.S., Bennett T.A., Hacker N.F. (2001) Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma Cells. J Natl Cancer Inst 93 : 1375 1384.
2. Peghini P.L., Iwamoto M., Raffeld M., Chen Y.-J., Goebel S.U., Serrano J., Jensen R.T. (2002) Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and Lower Curability. Clin Cancer Res 8 : 2273 2285.
3. Pedersen M.W., Meltorn M., Damstrup L., Poulsen H.S. (2001) The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 12 : 745 760.
4. Pedersen M.W., Poulsen H.S. (2002) Epidermal growth factor receptor in cancer therapy. Sci Med 8 : 206 217.
5. Lorimer I.A.J. (2002) Mutant epidermal growth factor receptors as targets for cancer therapy. Curr Cancer Drug Targets 2 : 91 102.
6. Ge H., Gong X., Tang C.K. (2002) Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer 98 : 357 361.
7. Sampson J.H., Crotty L.E., Lee S., Archer G.E., Ashley D.M., Wikstrand C.J., Hale L.P., Small C., Dranoff G., Friedman A.H., Friedman H.S., Bigner D.D. (2000) Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci U S A 97 : 7503 7508.
8. Modjtahedi H., Moscatello D.K., Box G., Green M., Shotton C., Lamb D.J., Reynolds L.J., Wong A.J., Dean C., Thomas H., Eccles S. (2003) Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy. Int J Cancer 10 : 273 280.
9. Omidfar K., Rasaee M.J., Modjtahedi H., Forouzandeh M., Taghikhani M., Bakhtiari A., Paknejad M., Kashanian S. (2004) Production and characterization of a new antibody specific for the mutant EGF receptor, EGFRvIII, in Camelus bactrianus. Tumour Biol 25 : 179 187.
10. Archer G.E., Sampson J.H., Lorimer I.A.J., McLendon R.E., Kuan C.-T., Friedman A.H., Friedman H.S., Pastan I.H., Bigner D.D. (1999) Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1. Clin Cancer Res 5 : 2646 2652.
11. Kuan C.-T., Wikstrand C.J., Bigner D.D. (2005) EGFRvIII as a promising target for antibody-based brain tumor therapy. Brain Tumor Pathol 17 : 71 78.
12. Muehlemann M., Miller K., Dauphinee M., Mizejewski G. (2005) Review of growth inhibitory peptide as a biotherapeutic agent for tumor growth, adhesion, and metastasis. Cancer Metastasis Rev 24 : 441 467.
13. Dane K.Y., Chan L.A., Rice J.J., Daugherty P.S. (2006) Isolation of cell specific peptide ligands using fluorescent bacterial display libraries. J Immunol Methods 309 : 120 129.
14. Disis M.L., Salazar L.G., Knutson K.L. (2004) Peptide-based vaccines in breast cancer. Breast Dis 20 : 3 11.
15. Toth F., Farkas J., Toth G., Wollemann M., Borsodi A., Benyhe S. (2003) Synthesis and binding characteristics of a novel enkephalin analogue, [3H]Tyr-D-Ala-Gly-Phe-D-Nle-Arg-Phe. Peptides 24 : 1433 1440.
16. Campa M.J., Kuan C.-T., O'Connor-McCourt M.D., Bigner D.D., Patz E.F. (2000) Design of a novel small peptide targeted against a tumor-specific receptor. Biochem Biophys Res Commun 275 : 631 636.
17. Fassina G., Cassani G. (1992) Design and recognition properties of a hydropathically complementary peptide to human interleukin 1β. Biochem J 282 : 773 779.
18. Sroka T.C., Marik J., Pennington M.E., Lam K.S., Cress A.E. (2006) The minimum element of a synthetic peptide required to block prostate tumor cell migration. Cancer Biol Ther 5 : 1556 1562.
19. McLean L.R., Hagaman K.A., Owen T.J., Krstenansky J.L. (1991) Minimal peptide length for interaction of amphipathic α-helical peptides with phosphatidylcholine liposomes. Biochemistry 30 : 31 37.
20. Pruss R.M., Herschman H.R. (1977) Variants of 3T3 cells lacking mitogenic response to epidermal growth factor. Proc Natl Acad Sci U S A 74 : 3918 3921.
21. Batra S.K., Castelino-Prabhu S., Wikstrand C.J., Zhu X., Humphrey P.A., Friedman H.S., Bigner D.D. (1995) Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 6 : 1251 1259.
22. Wells A., Welsh J.B., Lazar C.S., Wiley H.S., Gill G.N., Rosenfeld M.G. (1990) Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. Science 247 : 962 964.
23. Grandal M.V., Zandi R., Pedersen M.W., Willumsen B.M., van Deurs B., Poulsen H.S. (2007) EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes. Carcinogenesis 28 : 1408 1417.
24. Mosmann T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 16 : 55 63.
25. Chatellier J., Mazza A., Brousseau R., Vernet T. (1995) Codon-based combinatorial alanine scanning site-directed mutagenesis: design, implementation, and polymerase chain reaction screening. Anal Biochem 229 : 282 290.
26. Cunningham B.C., Wells J.A. (1989) High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science 244 : 1081 1085.
27. + T cells that are dependent on MHC class II-bound peptide-flanking residues. J Immunol 169 : 739 749.
28. Hamashin C., Spindler L., Russell S., Schink A., Lambkin I., O'Mahony D., Houghten R., Pinilla C. (2003) Identification of novel small-molecule Ulex europaeus I mimetics for targeted drug delivery. Bioorg Med Chem 11 : 4991 4997.
29. Chou P.Y., Fasman G.D. (1974) Prediction of protein conformation. Biochemistry 13 : 222 245.
30. Eisenberg D. (1984) Three-dimensional structure of membrane and surface proteins. Ann Rev Biochem 53 : 595 623.